Grantham, Mayo, Van Otterloo & Co (GMO)’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$690M Buy
749,815
+10,541
+1% +$10.7M 1.76% 19
2025
Q4
$794M Buy
739,274
+38,666
+6% +$37M 2.03% 18
2025
Q3
$535M Buy
700,608
+226,586
+48% +$169M 1.51% 20
2025
Q2
$370M Sell
474,022
-9,778
-2% -$7.6M 1.11% 29
2025
Q1
$400M Buy
483,800
+48,568
+11% +$40.4M 1.26% 27
2024
Q4
$336M Buy
435,232
+6,368
+1% +$5.27M 1.09% 29
2024
Q3
$380M Sell
428,864
-41,625
-9% -$37.4M 1.19% 26
2024
Q2
$426M Sell
470,489
-213,297
-31% -$171M 1.44% 24
2024
Q1
$532M Sell
683,786
-6,077
-0.9% -$4.32M 1.93% 18
2023
Q4
$402M Buy
689,863
+30,370
+5% +$17.7M 1.77% 18
2023
Q3
$354M Sell
659,493
-156,780
-19% -$80.8M 1.67% 17
2023
Q2
$383M Buy
816,273
+28,426
+4% +$11.9M 1.77% 14
2023
Q1
$271M Buy
787,847
+10,877
+1% +$3.67M 1.38% 19
2022
Q4
$284M Sell
776,970
-9,871
-1% -$3.5M 1.51% 18
2022
Q3
$254M Sell
786,841
-3,068
-0.4% -$972K 1.47% 16
2022
Q2
$256M Sell
789,909
-136,417
-15% -$40.9M 1.39% 18
2022
Q1
$265M Sell
926,326
-64,469
-7% -$16.6M 1.28% 20
2021
Q4
$274M Sell
990,795
-13,334
-1% -$3.38M 1.31% 20
2021
Q3
$232M Buy
1,004,129
+14,707
+1% +$3.63M 1.15% 22
2021
Q2
$227M Sell
989,422
-186,299
-16% -$37.4M 1.13% 22
2021
Q1
$220M Buy
1,175,721
+23,403
+2% +$4.58M 1.2% 23
2020
Q4
$195M Sell
1,152,318
-207,505
-15% -$31M 1.2% 25
2020
Q3
$201M Buy
1,359,823
+32,382
+2% +$5.01M 1.43% 24
2020
Q2
$218M Sell
1,327,441
-4,947
-0.4% -$759K 1.62% 21
2020
Q1
$185M Sell
1,332,388
-450,536
-25% -$61.9M 1.54% 22
2019
Q4
$234M Buy
1,782,924
+2,004
+0.1% +$232K 1.57% 19
2019
Q3
$199M Buy
1,780,920
+189,524
+12% +$21.1M 1.38% 24
2019
Q2
$176M Buy
1,591,396
+1,563,537
+5,612% +$184M 1.24% 25
2019
Q1
$3.62M Sell
27,859
-282,200
-91% -$34.3M 0.03% 329
2018
Q4
$35.9M Sell
310,059
-63,400
-17% -$7.08M 0.29% 63
2018
Q3
$40.1M Sell
373,459
-50,100
-12% -$5.01M 0.27% 70
2018
Q2
$36.1M Sell
423,559
-905,790
-68% -$74.4M 0.26% 60
2018
Q1
$103M Buy
1,329,349
+348,500
+36% +$28.1M 0.63% 44
2017
Q4
$82.8M Buy
980,849
+178,800
+22% +$15.2M 0.49% 50
2017
Q3
$68.6M Sell
802,049
-65,224
-8% -$5.35M 0.4% 58
2017
Q2
$71.4M Buy
867,273
+29,054
+3% +$2.37M 0.39% 61
2017
Q1
$70.5M Sell
838,219
-246,892
-23% -$19.8M 0.4% 65
2016
Q4
$79.8M Buy
1,085,111
+37,801
+4% +$2.82M 0.43% 61
2016
Q3
$84.1M Buy
1,047,310
+62,800
+6% +$5.03M 0.4% 61
2016
Q2
$77.5M Sell
984,510
-395,783
-29% -$29.8M 0.32% 75
2016
Q1
$99.4M Sell
1,380,293
-52,400
-4% -$3.96M 0.37% 60
2015
Q4
$121M Sell
1,432,693
-88,682
-6% -$7.36M 0.43% 58
2015
Q3
$127M Buy
1,521,375
+58,151
+4% +$4.91M 0.44% 50
2015
Q2
$122M Buy
1,463,224
+1,171,568
+402% +$89.3M 0.39% 57
2015
Q1
$21.2M Sell
291,656
-692,859
-70% -$49.3M 0.06% 134
2014
Q4
$67.9M Sell
984,515
-1,926,338
-66% -$130M 0.18% 86
2014
Q3
$189M Sell
2,910,853
-1,172,500
-29% -$74.2M 0.5% 43
2014
Q2
$254M Sell
4,083,353
-1,027,371
-20% -$61.3M 0.69% 37
2014
Q1
$301M Sell
5,110,724
-1,192,120
-19% -$66.5M 0.78% 31
2013
Q4
$321M Sell
6,302,844
-709,976
-10% -$35.6M 0.78% 29
2013
Q3
$353M Buy
7,012,820
+758,468
+12% +$39.7M 0.93% 27
2013
Q2
$307M Buy
+6,254,352
New +$340M 0.8% 29

Other funds holding LLY

Grantham, Mayo, Van Otterloo & Co (GMO)'s LLY Position: Q1 2026 in Review

Grantham, Mayo, Van Otterloo & Co (GMO) increased its Eli Lilly (LLY) stake by 1.4% in Q1 2026, buying an estimated $10.7M and bringing the position to 749,815 shares worth $690M. The position accounts for 1.76% of the portfolio, ranked #19.

Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in LLY in Q2 2013 and has held it in 52 quarters since. The position peaked at $794M in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Grantham, Mayo, Van Otterloo & Co (GMO) held 749,815 shares of Eli Lilly worth $690M as of Q1 2026.
  • Grantham, Mayo, Van Otterloo & Co (GMO) bought 10,541 Eli Lilly shares in Q1 2026, an estimated $10.7M.
  • Eli Lilly made up 1.76% of Grantham, Mayo, Van Otterloo & Co (GMO)'s portfolio in Q1 2026, its #19 holding.
  • Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in Eli Lilly in Q2 2013 and has held it in 52 quarters since.
  • Grantham, Mayo, Van Otterloo & Co (GMO)'s Eli Lilly position peaked at $794M in Q4 2025.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Grantham, Mayo, Van Otterloo & Co (GMO)'s 13F filing for Q1 2026, filed 14 May 2026.